RxDoctor Payments Data

Yaniv Chen

Neurology · Stratford, CTNPI 1710183314

Payments from drug & device makers

$28,271in general payments, 2019–2025

Across 1,399 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$6K
  • AbbVie$4K
  • UCB, Inc.$2K
  • Novartis$2K
  • Biogen$1K
  • SK Life Science, Inc.$1K
  • plus $13K from 52 others

What the payments were for

  • Consulting fees$4,19515%
  • Speaking & faculty fees$680%
  • Travel & lodging$3841%
  • Food & beverage$23,53583%
  • Education$880%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.47$5,659
AbbVie(2 entities)219$3,510
UCB, Inc.111$1,940
Novartis127$1,645
Biogen81$1,470
SK Life Science, Inc.89$1,403
Genentech USA, Inc.53$1,106
Teva Pharmaceuticals USA, Inc.60$1,028
Amneal Pharmaceuticals LLC57$858
Acadia Pharmaceuticals Inc53$850
Argenx US, Inc.27$649
Lilly USA, LLC38$641
Amgen(2 entities)26$546
Lundbeck LLC33$523
Biohaven Pharmaceutical Holding Company Ltd.30$510
AstraZeneca28$495
Supernus Pharmaceuticals, Inc.36$477
EMD Serono, Inc.29$442
Pfizer28$414
Bristol Myers Squibb18$364
Kyowa Kirin, Inc.21$347
Avanir Pharmaceuticals, Inc.15$300
MDD US Operations, LLC21$272
Biohaven Pharmaceuticals, Inc.15$261
Sanofi15$260
Tris Pharma Inc19$243
TG Therapeutics, Inc.7$208
Otsuka America Pharmaceutical, Inc.9$180
Corium, LLC6$153
Sunovion Pharmaceuticals Inc.11$153
Neurocrine Biosciences, Inc.6$137
Shire North American Group Inc6$133
Axsome Therapeutics, Inc.5$129
Adlon Therapeutics L.p.6$97
Adamas Pharmaceuticals, Inc.5$89
Acorda Therapeutics, Inc5$88
Upsher-smith Laboratories LLC4$72
Alnylam Pharmaceuticals Inc.2$51
Currax Pharmaceuticals LLC3$49
Avion Pharmaceuticals2$46
Octapharma USA, Inc.2$43
Ironshore Pharmaceuticals Inc.2$42
Sumitomo Pharma America, Inc.4$41
Arbor Pharmaceuticals, Inc.2$38
Takeda Pharmaceuticals U.S.A., Inc.2$38
Impel Pharmaceuticals Inc.2$33
Vertical Pharmaceuticals, LLC1$25
E.r. Squibb & Sons, L.L.C.1$25
Impel Pharmaceuticals LLC1$23
Abbott1$23
Idorsia Pharmaceuticals US Inc1$21
Akcea Therapeutics, Inc.1$20
Merz Pharmaceuticals, LLC1$20
CSL Behring1$19
Mallinckrodt Hospital Products Inc.1$17
Aprecia Pharmaceuticals, LLC1$16
Promius Pharma LLC1$15
Assertio Therapeutics, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,271 in reported general payments places this provider in the 75th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$1,133,864
Medicare patients
300
Services billed
154,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin17$244,943
NuplazidPimavanserin Tartrate40$221,448
RytaryCarbidopa/Levodopa170$205,021
AubagioTeriflunomide14$135,324
BriviactBrivaracetam39$63,952
Nurtec OdtRimegepant Sulfate29$42,211
NeuproRotigotine25$34,686
Emgality PenGalcanezumab-Gnlm46$32,842
GocovriAmantadine Hcl14$29,604
QuliptaAtogepant27$28,790
LamictalLamotrigine21$24,631
UbrelvyUbrogepant13$19,404
BotoxOnabotulinumtoxina13$17,081
Ajovy AutoinjectorFremanezumab-Vfrm21$15,312
Keppra XrLevetiracetam11$14,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$442$244,94317 claims
Acadia Pharmaceuticals IncNuplazid$850$221,44840 claims
Amneal Pharmaceuticals LLCRytary$858$205,021170 claims
SanofiAubagio$260$135,32414 claims
UCB, Inc.Briviact, Neupro$1,940$98,63864 claims
AbbVieQulipta, Ubrelvy, Botox$3,510$65,27553 claims
PfizerNurtec Odt, Dilantin$414$47,24046 claims
MDD US Operations, LLCGocovri$272$29,60414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 280 neurology providers in Connecticut.

Other neurology in Stratford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →